Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 5,521 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Hirschsprung Disease
Interventions: VSL#3, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 1 Month to 12 Months
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Buffalo, New York

Conditions: Age-Associated Memory Impairment
Interventions: Tricaprilin, Placebo; Drug · Other
Lead sponsor: Cerecin; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Brooksville, Florida • DeLand, Florida • Naples, Florida + 3 more

Conditions: Parkinson's Disease
Interventions: PYM50028, Placebo; Drug
Lead sponsor: Phytopharm; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Erlotinib, Onartuzumab (MetMab), Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 56
States / cities: Chandler, Arizona • Hayward, California • Modesto, California + 47 more

Conditions: Ulcerative Colitis
Interventions: deligoparin; Drug
Lead sponsor: Incara Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 33
States / cities: Anaheim, California • Orange, California • Lakewood, Colorado + 29 more

Conditions: Pregnancy
Interventions: Probiotic dietary supplement; Dietary Supplement
Lead sponsor: Marquette University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Crohn's Disease
Interventions: Naltrexone, Placebo, sugar pill; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more

Conditions: Asthma
Interventions: GB001, Placebo; Drug
Lead sponsor: GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 41 more

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, Interstitial Lung Disease, Lung Diseases, Interstitial
Interventions: CC-930, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 50 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 16
States / cities: Birmingham, Alabama • Sacramento, California • Stanford, California + 13 more

Conditions: Alcohol Drinking
Interventions: Memantine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 58
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Molluscum Contagiosum
Interventions: SB206 12%, Placebo; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 27
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 24 more

Conditions: Inclusion Body Myositis
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Kansas City, Kansas • Baltimore, Maryland

Conditions: Dementia-related Psychosis
Interventions: Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 27
States / cities: Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more

Conditions: Psoriasis
Interventions: PF-06700841, Vehicle (Placebo); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Anaheim, California + 31 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: Ciclesonide nasal spray + placebo Azelastine, Ciclesonide nasal spray + Azelastine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 35
States / cities: Encinitas, California • Los Angeles, California • Mission Viejo, California + 32 more

Conditions: Unresectable Hepatocellular Carcinoma
Interventions: ARQ 197, Placebo; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Galveston, Texas

Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions: Atumelnant, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more

Conditions: Healthy
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Ketosis
Interventions: Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Breath Reading, Heart Rate Variability, CGM/CKM, DXA, Urine Analysis; Dietary Supplement · Behavioral · Biological + 2 more
Lead sponsor: Ohio State University; Other
Eligibility: 20 Years to 30 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Parkinson Disease Psychosis
Interventions: SEP-363856, Placebo capsule; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 55 Years to 105 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 24
States / cities: Fresno, California • Los Angeles, California • Riverside, California + 19 more

Conditions: Head and Neck Cancer
Interventions: Pulmozyme, Placebo, Radiation Therapy; Drug · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acne Vulgaris
Interventions: CD2475/101 40 mg, Doxycycline 100 mg, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more

Search by objective public record fields.

Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)

Tricaprilin In Age-Associated Memory Impairment

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis

Quasi Experiment of Prenatal Probiotics Against Group B Streptococcus Colonization

The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

GB001 in Adult Subjects With Moderate to Severe Asthma

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Family History Study of Alcohol Consumption Using Memantine

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

Phase III Trial of Sirolimus in IBM

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris